SAN FRANCISCO--(BUSINESS WIRE)--Data from a multicenter registry of targeted renal therapy (TRT®) in patients at high risk for acute kidney injury – a common complication of hospitalized patients and one that is associated with increased short and long-term mortality -- was presented Sunday at the American Society of Nephrology’s Renal Week 2007 by James A. Tumlin, M.D., nephrologist, Clinical Research Division, Southeast Renal Associates, Charlotte, N.C. TRT is the delivery of physician-specified therapeutic agents directly to the kidneys via the renal arteries through the innovative Benephit Infusion Systems from FlowMedica, Inc. TRT may offer significant benefit in direct infusion of therapeutic levels of medications without the side effects that can be encountered with conventional IV delivery.
